Article
A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients.
Investigational new drugs - 1 Oct 2014
Spreafico Anna, Chi Kim N, Sridhar Srikala S, Smith David C, Carducci Michael A, Kavsak Peter, Wong Tracy S, Wang Lisa, Ivy S Percy, Mukherjee Som Dave, Kollmannsberger Christian K, Sukhai Mahadeo A, Takebe Naoko, Kamel-Reid Suzanne, Siu Lillian L, Hotte Sebastien J
Abstract excerpt
BACKGROUND: Activation of the vascular endothelial growth factor receptor (VEGFR) and the oncogenic Src pathway has been implicated in the development of castration-resistant prostate cancer (CRPC) in preclinical models. Cediranib and dasatinib are multi-kinase inhibitors targeting VEGFR and Src respectively. Phase II studies of cediranib and dasatinib in CRPC have shown single agent activity. METHODS:...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.